Investment archive

Investment feed — page 8

Back to latest investments

Mosaico announces €7.5M Seed led by United Ventures for physical-AI data

Mosaico announces €7.5M Seed led by United Ventures for physical-AI data

Original lead-investor statement confirms €7.5M NEW seed with OpenOcean and Connect Ventures; do not substitute the reported €8.5M cumulative funding. Legal close day and valuation undisclosed.

Dreamteam discloses $53M combined Seed and Series A funding for AI-native CRM

Dreamteam discloses $53M combined Seed and Series A funding for AI-native CRM

Dreamteam's company-issued November 16, 2026 announcement disclosed $53M cumulatively raised across Seed and Series A financing. TechCrunch's independent interview identifies Together Fund as the Seed lead, Accel as Series A lead and Premji Invest as participant. This is ONE combined historical disclosure of two separate rounds, NOT a newly completed $53M Series A; individual tranche amounts, exact legal close dates, total valuation, current revenue and ARR are UNDISCLOSED. The company sells an AI-native CRM with four agent coworkers and first-party publicly listed pricing of $49 per active seat per month plus $30 monthly shared AI credit packs; the company reports customers but their usage is not audited. Do not add future projected sales targets or treat vendor-reported customer benefits as revenue.

Stark Future closes financing with more than €150M total transaction value at €1.2B pre-money valuation

Stark Future closes financing with more than €150M total transaction value at €1.2B pre-money valuation

Issuer and participating investor on Nov 16 confirmed a CLOSED financing transaction with MORE THAN €150M in TOTAL transaction value, led by Highland Europe with Morgan Stanley 1GT and Axon. Company reports €1.2B PRE-money valuation. Breakdown between fresh primary company cash and potential secondary or other deal components was NOT disclosed. A possible second closing remains uncompleted. Product is a commercial VARG electric motorcycle range, not a preclinical concept. €150M is a strict lower bound on deal value, not precise cash raised.

Seawolf Therapeutics discloses $100M total across Seed and Series A, announces separate Sanofi pact

Seawolf Therapeutics discloses $100M total across Seed and Series A, announces separate Sanofi pact

Seawolf publicly emerged November 16, 2026, disclosing $100M cumulatively raised in a Versant-led seed followed by a Series A involving Versant, MPM BioImpact, Novartis Venture Fund and others. Individual seed/A amounts and legal closing days are undisclosed; this is ONE combined historical disclosure, not a $100M Series A. A distinct Sanofi research/license arrangement includes up to $1.2B conditional milestones and royalties, NOT $1.2B startup financing, initial cash or company valuation. TRIDENT DNA-LNP clinical results remain preclinical.

Corma raises $125M Series A led by NEA at reported $1B valuation

Corma raises $125M Series A led by NEA at reported $1B valuation

Issuer-announced November 16, 2026 Series A of $125M led by New Enterprise Associates; existing investors Sequoia, Khosla Ventures and Coatue participated. The company reports $185M cumulative disclosed equity funding after its separate August $60M seed. The $1B valuation's pre/post-money basis and precise closing day are not specified; company claims about autonomous security outcomes are unverified commercial metrics.

Johnson & Johnson agrees to acquire Ollin for $2.2B upfront plus up to $1.125B milestones

Johnson & Johnson agrees to acquire Ollin for $2.2B upfront plus up to $1.125B milestones

Nov 16 definitive acquisition agreement, not yet legally closed. $2.2B cash upfront plus up to approximately $1.125B in future regulatory and commercial payments; maximum contingent transaction consideration about $3.325B. Separately Blackstone will fund $750M toward J&J's Phase 3 program across multiple years for milestones and royalties. That development funding is NOT acquisition consideration or new Ollin equity. OLN324 investigational; close targeted before end of 2026.

Lilly agrees to buy Calytrix Bio for up to $1.5B including contingent clinical milestones

Lilly agrees to buy Calytrix Bio for up to $1.5B including contingent clinical milestones

Definitive agreement announced November 16, not completed acquisition. Maximum possible $1.5B cash to Calytrix shareholders comprises undisclosed upfront consideration and additional clinical/regulatory milestone payments. Actual upfront, certainty of milestones, and legal close date undisclosed. Calytrix remains private pending confirmed close.

Remedy Robotics announces $62M Series B led by DCVC for investigational N1 system

Remedy Robotics announces $62M Series B led by DCVC for investigational N1 system

Company-disclosed $62M Series B for pivotal clinical study preparation, FDA regulatory pathway and N1 prototypes. DCVC leads; UC Investments, Skip Capital, Hostplus and existing backers participate. N1 is investigational, not commercially available or approved. Legal financing closing date and valuation undisclosed.

Galvanize Therapeutics closes $130M Series D led by HealthQuest Capital

Galvanize Therapeutics closes $130M Series D led by HealthQuest Capital

Issuer-confirmed completed $130M Series D; funds expansion of FDA-cleared soft-tissue ablation platform Aliya, clinical studies and RheOx development. Over 4,000 procedures claimed; no disease-specific cancer treatment approval, company valuation or standalone legal closing date disclosed beyond November 16 press statement.

Sofinnova Crossover II announces €725M final close for clinical-stage life sciences

Sofinnova Crossover II announces €725M final close for clinical-stage life sciences

The €725M FINAL close is cumulative fund commitments, not new November cash or a biotech portfolio-company financing. About 15 companies targeted; Hemab, CellCentric and Neurent Medical already backed. European Tech Champions Initiative/EIF supported; EIB 2024 report lists €250M EIF signature, not additional 2026 capital. Exact legal closing date undisclosed. On 18 November 2026, British Business Bank separately disclosed a €58M LP commitment included in the existing fund total, not incremental funding; the exact LP signing date is unspecified.

Plural announces €1B combined raise across Fund III and separate follow-on fund

Plural announces €1B combined raise across Fund III and separate follow-on fund

Plural's manager-issued November 16 announcement covers €1B collectively across early-stage Fund III and an opportunities fund for follow-ons. Partner interviews describe two-thirds/one-third allocations, not precise vehicle totals. British Business Bank separately confirms its €75M LP commitment to Plural without a per-vehicle breakdown. Exact legal closes remain undisclosed.

vVARDIS completes $175M NYSE IPO: Nov 13 trading, Nov 16 legal close

vVARDIS completes $175M NYSE IPO: Nov 13 trading, Nov 16 legal close

vVARDIS Holding AG priced 9,722,223 Class A ordinary shares at $18 per share in its November 2026 NYSE IPO (VVVV), yielding exactly $175,000,014 base GROSS offering proceeds before underwriting deductions and expenses. Trading began on November 13, 2026. The issuer's signed SEC Form 6-K dated November 16 confirms the IPO LEGALLY CLOSED on November 16, with the same 9,722,223 base shares. Underwriters' separately disclosed 30-day option for up to 1,458,333 additional shares was not represented as exercised in this filing; exclude it from base proceeds. Historical OrbiMed financing in 2025 ($35M then $50M) is unrelated to IPO proceeds and its debt/equity instrument split must not be invented. This canonical event retains the original trading-debut eventDate and stable eventKey.